Literature DB >> 1267250

Effect of helium on maximal expiratory flow in patients with asthma before and during induced bronchoconstriction.

M Chan-Yeung, R Abboud, M S Tsao, L Maclean.   

Abstract

The effect of breathing helium on maximal expiratory flow at 50 per cent of vital capacity (V50) was studied in 27 patients with asthma during remission and during induced bronchoconstriction. Nine patients gave a history of asthma induced by exercise; two had asthma due to timothy pollen allergy, and the remaining 16 had asthma due to exposure to western red cedar. Bronchoconstriction was induced by exercise in 10 patients, timothy pollen in 4 patients, methacholine in 4 patients, and red cedar in 16 patients. During remission, the increase in V50 with helium (deltaV50He) was greater than 20 per cent in 22 patients who were classified as responders; deltaV50He was less than 20 per cent in the remaining 5 patients, who were classified as nonresponders. There was a significant correlation between the severity of airway obstruction as measured by V50 and the response to helium, both during remission and during induced bronchoconstriction; however, there was no correlation between helium response and specific airway conductance. In general, patients who were responders during remission remained responders during induced bronchoconstriction, and nonresponders remained nonresponders, regardless of the method of challenge or the type of reaction (immediate verus late). There were a few exceptions in which a responder became a nonresponder during severe bronchoconstriction. The results of this study suggest that in most patients with asthma, the site of airway obstruction is likely to be in the large airways and, in most cases, remains constant in an individual asthmatic; however, an asthmatic who is a helium responder may become a nonresponder during severe bronchoconstriction.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1267250     DOI: 10.1164/arrd.1976.113.4.433

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  14 in total

1.  Influence of antigen challenge on density dependence of maximal expiratory flow and nitrogen washout curves in extrinsic bronchial asthma.

Authors:  G W Sybrecht; U H Winkler; H Fabel
Journal:  Lung       Date:  1979       Impact factor: 2.584

Review 2.  Exercise-induced asthma.

Authors:  P A Eggleston
Journal:  Clin Rev Allergy       Date:  1983-03

3.  Cotton induced bronchoconstriction detected by a forced random noise oscillator.

Authors:  M J Sepulveda; J L Hankinson; R M Castellan; J B Cocke
Journal:  Br J Ind Med       Date:  1984-11

4.  Helium-oxygen spirometry in experimental cotton dust exposure.

Authors:  M J Sepulveda; J L Hankinson; R M Castellan; J B Cocke
Journal:  Lung       Date:  1984       Impact factor: 2.584

5.  Effect of fenoterol on small airways and regional lung function in asymptomatic asthma.

Authors:  R Sergysels; G Scano; J Vrebos; M Bracamonte; J Vandevivere
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Site of airway obstruction in asymptomatic asthmatic children.

Authors:  J Loke; M Ganeshananthan; C R Palm; E K Motoyama
Journal:  Lung       Date:  1981       Impact factor: 2.584

7.  Imaging sites of airway obstruction and measuring functional responses to bronchodilator treatment in asthma.

Authors:  S K Chopra; G V Taplin; D P Tashkin; E Trevor; D Elam
Journal:  Thorax       Date:  1979-08       Impact factor: 9.139

8.  Reproducibility of flow rates measured with low density gas mixtures in exercise-induced bronchospasm.

Authors:  S G Spiro; C W Bierman; I S Petheram
Journal:  Thorax       Date:  1981-11       Impact factor: 9.139

9.  A comparative study of beta-adrenoceptors in human and porcine lung parenchyma strip.

Authors:  R G Goldie; J W Paterson; J L Wale
Journal:  Br J Pharmacol       Date:  1982-08       Impact factor: 8.739

10.  Sodium cromoglycate and ipratropium bromide in exercise-induced asthma.

Authors:  N C Thomson; K R Patel; J W Kerr
Journal:  Thorax       Date:  1978-12       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.